Literature DB >> 20025049

Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening.

D Hayes1, P M Farrell, Z Li, S E West.   

Abstract

BACKGROUND: With newborn screening (NBS) for cystic fibrosis (CF), eradication of Pseudomonas aeruginosa (PA) is possible if PA detection occurs early. A serological response to infection likely precedes culture positivity in CF patients, so PA serological testing is very appealing in this population. However, controversies continue to exist about serology testing, titer cutoffs for enzyme-linked immunosorbent assay (ELISA) antibody tests, and their value in children with CF.
METHODS: This longitudinal, prospective study collected respiratory secretions as oropharyngeal swabs or expectorated sputum for culture and also sera over 6 years in 69 patients diagnosed by NBS. Serology assessed PA antibody titers against cell lysate, exotoxin A, and elastase. A novel statistical approach with weighted receiver operating characteristic (ROC) curves was used to determine best antibody titer cutoff values to predict subsequent PA positive cultures.
RESULTS: Using these weighted ROC curves, the order of sensitivity was found to be cell lysate, exotoxin A, and then elastase while age-specific cutoffs were better than fixed cutoffs previously used. Age-specific serological cutoffs both predict and detect PA respiratory infections with a higher sensitivity and specificity. Serological responses to the PA antigens determined that a response to cell lysate occurs significantly earlier than culture positivity.
CONCLUSIONS: Age-specific serological cutoffs rather than fixed values against common PA antigens improve early PA identification in infants and young children diagnosed with NBS. Regular serological assessment with age-specific cutoffs in these children appears to be a worthy diagnostic tool. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20025049      PMCID: PMC2924665          DOI: 10.1002/ppul.21083

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  21 in total

1.  Pseudomonas serology: confusion, controversy, and challenges.

Authors:  P M Farrell; J R W Govan
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

Review 2.  Detection of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  G A Tramper-Stranders; C K van der Ent; T F W Wolfs
Journal:  J Cyst Fibros       Date:  2005-08       Impact factor: 5.482

3.  Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1986-11       Impact factor: 3.791

4.  IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA.

Authors:  T Pressler; S S Pedersen; F Espersen; N Høiby; C Koch
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

5.  Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis.

Authors:  M Rosenfeld; J Emerson; F Accurso; D Armstrong; R Castile; K Grimwood; P Hiatt; K McCoy; S McNamara; B Ramsey; J Wagener
Journal:  Pediatr Pulmonol       Date:  1999-11

6.  Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients.

Authors:  Felix Ratjen; Hanna Walter; Maria Haug; Christoph Meisner; Hartmut Grasemann; Gerd Döring
Journal:  Pediatr Pulmonol       Date:  2007-03

7.  Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M Kappler; A Kraxner; D Reinhardt; B Ganster; M Griese; T Lang
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

8.  Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

Authors:  P M Farrell; M R Kosorok; A Laxova; G Shen; R E Koscik; W T Bruns; M Splaingard; E H Mischler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

9.  Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients.

Authors:  B W Ramsey; K R Wentz; A L Smith; M Richardson; J Williams-Warren; D L Hedges; R Gibson; G J Redding; K Lent; K Harris
Journal:  Am Rev Respir Dis       Date:  1991-08

10.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

View more
  5 in total

1.  Pseudomonas aeruginosa in the Cystic Fibrosis Lung.

Authors:  John King; Ronan Murphy; Jane C Davies
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Authors:  Michael Anstead; Sonya L Heltshe; Umer Khan; Joseph T Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L Gibson; Miriam M Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

Review 3.  Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment.

Authors:  Luiz Vicente Ribeiro Ferreira da Silva Filho; Flavia de Aguiar Ferreira; Francisco José Caldeira Reis; Murilo Carlos Amorim de Britto; Carlos Emilio Levy; Otavio Clark; José Dirceu Ribeiro
Journal:  J Bras Pneumol       Date:  2013 Jun-Aug       Impact factor: 2.624

4.  Detection of algD, oprL and exoA Genes by New Specific Primers as an Efficient, Rapid and Accurate Procedure for Direct Diagnosis of Pseudomonas aeruginosa Strains in Clinical Samples.

Authors:  Sedighe Rashno Taee; Behzad Khansarinejad; Hamid Abtahi; Mohammad Najafimosleh; Ehsanollah Ghaznavi-Rad
Journal:  Jundishapur J Microbiol       Date:  2014-10-01       Impact factor: 0.747

5.  Evolving serodiagnostics by rationally designed peptide arrays: the Burkholderia paradigm in Cystic Fibrosis.

Authors:  Claudio Peri; Alessandro Gori; Paola Gagni; Laura Sola; Daniela Girelli; Samantha Sottotetti; Lisa Cariani; Marcella Chiari; Marina Cretich; Giorgio Colombo
Journal:  Sci Rep       Date:  2016-09-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.